Showing results (361-370 of 390) with videos related to
Sort By:
Pageof 39
Multiple Sclerosis and Related Disorders|February 15, 2022
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Sean J Pittock, Friedemann Paul, et al.Therapeutic Advances in Neurological Disorders|December 25, 2010
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosisElliot M Frohman, Gary Cutter, Gina Remington, et al.Annals of Neurology|August 19, 2007
Health-related quality of life in multiple sclerosis: effects of natalizumabRichard A Rudick, Deborah Miller, Steve Hass, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2024
Cognitive rehabilitation effects on grey matter volume and Go-NoGo activity in progressive multiple sclerosis: results from the CogEx trialMaria A Rocca, Paola Valsasina, Francesco Romanò, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.Journal of Parkinson'S Disease|December 13, 2021
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD TrialM Judith Peterschmitt, Hidemoto Saiki, Taku Hatano, et al.Neuro-Oncology|April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.Annals of Neurology|August 28, 2023
Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT TrialElizabeth Martina Bebin, Jurriaan M Peters, Brenda E Porter, et al.American Journal of Physiology. Lung Cellular and Molecular Physiology|June 14, 2022
Absolute quantification of plasma mitochondrial DNA by droplet digital PCR marks COVID-19 severity over time during intensive care unit admissionsMark L Hepokoski, Mazen Odish, Michael T Lam, et al.Annals of Clinical and Translational Neurology|May 8, 2024
Polygenic liability for anxiety in association with comorbid anxiety in multiple sclerosisKaarina Kowalec, Arvid Harder, Casandra Dolovich, et al.Pageof 39